Some disease areas bucked the trend of shrinking pipelines, however, with immune and cardiovascular indications seeing an ...

The number of drugs in development has fallen for the first time since the mid-1990s, according to a Citeline report. | The ...

This acquisition will add Syfovre and Empaveli to Biogen’s portfolio of medicines.

Systemic Lupus Erythematosus Clinical Trial Pipeline Accelerates as 120+ Pharma Companies Rigorously Developing Drugs for Market Entry | DelveInsight The SLE clinical trial analysis report delivers ...

The deal secures two sleep disorder drugs that would fill a hole in the company’s portfolio and intensify a competition with ...

A new oral GLP-1 therapy and the first preventive option for COVID-19 are among the pipeline drugs that payers and plan ...

Pharma stocks draw interest as pipelines, clinical trials and acquisitions support growth outlook despite patent expiry ...

Merck is bulking up its portfolio ahead of its best-selling cancer drug Keytruda losing patent protection in 2028.

Oncology M&A activity is accelerating as large pharmaceutical companies race to replenish pipelines facing patent cliffs and ...

Overall, the top 16 largest pharmaceutical companies spent $159 billion on research and development in 2025, compared to $165 ...

GEORGETOWN, Texas & SOMERSET, N.J.--(BUSINESS WIRE)--DisperSol Technologies, a clinical-stage pharmaceutical company developing new treatments for oncology and rare diseases, and Catalent, the leading ...